Melanotan II and winter tanning: what TikTok won't tell you
Quick answer
Melanotan II is a synthetic melanocortin receptor agonist that stimulates melanogenesis, producing increased skin pigmentation with reduced UV exposure, a mechanism confirmed in clinical literature. However, it has never received FDA approval for any indication and carries documented risks including mole changes, nausea, and cardiovascular effects due to its nonselective receptor binding. Its use outside a supervised clinical setting raises significant safety concerns, particularly given unregulated supply chains and the absence of long-term human safety data.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @realnickcalabrese actually say?
Nick said he injected melanotan II (MT2) before a tanning bed session and claimed he got noticeable color after only five minutes. His framing was practical: MT2 is "such a good tool in the winter" for getting a tan with minimal UV exposure. That is the core claim, and it is worth unpacking carefully.
He is describing a real pharmacological mechanism, not a fabricated one. MT2 does stimulate melanin production by activating melanocortin receptors, particularly MC1R, which triggers melanogenesis in skin cells. So the color he saw the next day is plausible. What he does not address is the risk profile, the regulatory status, or the fact that this compound has never been approved by the FDA for any use, cosmetic or otherwise.
Does the science back this up?
Yes, partially, but the research context is more complicated than a five-minute tanning bed clip suggests. MT2 (melanotan II) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It binds nonselectively to melanocortin receptors, which is why it works for tanning but also produces a range of side effects.
Dorr et al. (1996, Journal of Investigative Dermatology) demonstrated that MT2 increased skin pigmentation in human subjects, and participants required less UV exposure to achieve equivalent tanning compared to controls. That is the study underpinning the "less time in the bed" claim, and it is legitimate data. However, the same research flagged spontaneous erections, nausea, and facial flushing as common adverse effects. Langan et al. (2020, British Journal of Dermatology) reviewed melanocortin peptides and raised concern about the lack of long-term safety data, particularly regarding changes in nevi (moles) and theoretical melanoma risk with repeated stimulation of melanocytes.
What did they get wrong (or right)?
Nick got the mechanism right. MT2 does amplify UV-induced tanning, and five minutes producing visible color is consistent with published dose-response data. Credit where it is due.
What is missing is everything else. MT2 is not a regulated, approved compound. It is sold as a research chemical, meaning quality control is inconsistent across suppliers. Injecting an unverified peptide carries infection risk, dosing uncertainty, and the possibility of receiving a mislabeled or contaminated product. He does not mention any of this.
More seriously, the claim that MT2 lets you "barely use the bed" as if UV reduction solves the risk equation is misleading. Reduced UV time helps, but MT2 itself stimulates melanocytes in ways that go beyond simple tanning. The compound activates multiple melanocortin receptor subtypes indiscriminately. Selective MC1R agonists are under investigation precisely because the nonselective binding of MT2 causes nevi changes in some users. Kadekaro et al. (2010, Pigment Cell and Melanoma Research) documented this concern. Treating MT2 as a low-risk winter beauty hack undersells what the compound actually does.
What should you actually know?
If you are considering MT2 for cosmetic tanning, there are several things that deserve more than a 30-second TikTok mention.
- MT2 has never received FDA approval. It is classified as a research chemical, not a therapeutic compound, which means no legal, supervised clinical pathway exists for its cosmetic use in the United States.
- Side effects from MT2 are well-documented and include nausea, spontaneous erections in men, facial flushing, and fatigue, even at low doses (Dorr et al., 1996).
- Changes in existing moles have been reported with MT2 use. If you have a personal or family history of melanoma, this is not a compound to experiment with casually.
- The "less UV" argument does not eliminate tanning bed risk. Tanning beds use UVA-dominant light, which penetrates deeper into the dermis and is associated with photoaging and skin cancer independent of burn risk.
- Because MT2 is sold without pharmaceutical oversight, purity and concentration vary by source. You do not know what you are injecting.
A dermatologist or regulated telehealth provider is the appropriate place to have this conversation if you are interested in melanocortin peptide research, not a tanning bed selfie.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Melanotan II and winter tanning: what TikTok won't tell you, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
SCENESSE (afamelanotide implant) FDA Prescribing Information
Afamelanotide (an alpha-MSH analog) is the only FDA-approved melanocortin peptide of this class, and only to increase pain-free light exposure in erythropoietic protoporphyria, not for cosmetic tanning.
FDA
Afamelanotide for Erythropoietic Protoporphyria
Randomized placebo-controlled trials (NEJM) behind the afamelanotide approval; this is the legitimate human melanocortin evidence, distinct from unapproved tanning peptides.
PubMed
The human peptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging
Anchor review for copper peptide gene-expression and tissue-repair claims.
PubMed
Effects of glycyl-histidyl-lysine-Cu on wound healing
Search-backed PubMed trail for wound-healing claims where specific topical versus injectable context matters.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Melanotan II and winter tanning: what TikTok won't tell you is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
Melanotan II is a synthetic melanocortin receptor agonist that stimulates melanogenesis, producing increased skin pigmentation with reduced UV exposure, a mechanism confirmed in clinical literature.
FormBlends verdict
Melanotan II is a synthetic melanocortin receptor agonist that stimulates melanogenesis, producing increased skin pigmentation with reduced UV exposure, a mechanism confirmed in clinical literature. However, it has never received FDA approval for any indication and carries documented risks including mole changes, nausea, and cardiovascular effects due to its nonselective receptor binding. Its use outside a supervised clinical setting raises significant safety concerns, particularly given unregulated supply chains and the absence of long-term human safety data.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Melanotan II is a synthetic melanocortin receptor agonist that stimulates melanogenesis, producing increased skin pigmentation with reduced UV exposure, a mechanism confirmed in clinical literature. However, it has never received FDA approval for any indication and carries documented risks including mole changes, nausea, and cardiovascular effects due to its nonselective receptor binding. Its use outside a supervised clinical setting raises significant safety concerns, particularly given unregulated supply chains and the absence of long-term human safety data.
- MT2 activates melanocortin receptors (MC1R and others) to increase melanin production, confirmed in human studies by Dorr et al., 1996, Journal of Investigative Dermatology.
- MT2 has never been approved by the FDA for any indication, cosmetic or therapeutic, and is sold legally only as a research chemical.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- MT2 activates melanocortin receptors (MC1R and others) to increase melanin production, confirmed in human studies by Dorr et al., 1996, Journal of Investigative Dermatology.
- MT2 has never been approved by the FDA for any indication, cosmetic or therapeutic, and is sold legally only as a research chemical.
- Documented side effects include nausea, spontaneous erections, facial flushing, and fatigue, even at low doses, per the original Dorr 1996 clinical data.
- Kadekaro et al. (2010, Pigment Cell and Melanoma Research) raised concerns about nevi changes with MT2 use, making it a poor fit for anyone with a personal or family history of melanoma.
- Tanning beds emit primarily UVA radiation, which penetrates the dermis and is independently associated with photoaging and skin cancer, so less time in the bed does not eliminate UV risk.
- Unregulated supply chains for research peptides mean purity and concentration are not guaranteed, creating an additional layer of risk beyond the compound's known pharmacology.
- Langan et al. (2020, British Journal of Dermatology) concluded that long-term safety data for MT2 in humans remains insufficient to characterize its use as low-risk.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Nick · TikTok creator
305.5K views on this video
Staying tan in the winter
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Nick, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.